Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by targeting the BIM-Bax/Bak axis in breast cancer

Tumor Biology

Volumn 37, Issue 4, 2016, Pages 4509-4515

  Ye, Zhiqiang ^a   Hao, Rutian ^a   Cai, Yefeng ^a   Wang, Xiaobo ^a   Huang, Guanli ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Anti miR 221; Bak; Bax; BIM; Breast cancer; DDP

Indexed keywords

BIM PROTEIN; CISPLATIN; MESSENGER RNA; MICRORNA 221; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; 3' UNTRANSLATED REGION; ANTINEOPLASTIC AGENT; BAK1 PROTEIN, HUMAN; BAX PROTEIN, HUMAN; MICRORNA; MIRN221 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BIM GENE; BREAST CANCER; BREAST CANCER CELL LINE; BREAST CARCINOGENESIS; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG CYTOTOXICITY; DRUG SENSITIVITY; DRUG TARGETING; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; IN VITRO STUDY; MDA MB 231 CELL LINE; MDA MB 435 CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR DYNAMICS; MTT ASSAY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T 47D CELL LINE; UPREGULATION; BINDING SITE; BREAST NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; RNA INTERFERENCE; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-2-ASSOCIATED X PROTEIN; BCL-2-LIKE PROTEIN 11; BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICRORNAS; RNA INTERFERENCE;

EID: 84945245355     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4267-4     Document Type: Article

References (29)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.
2. Matsen CB, Neumayer LA. Breast cancer: a review for the general surgeon. JAMA Surg. 2013;148:971–80.
3. Gradishar WJ. Treatment of metastatic breast cancer. J Natl Compr Cancer Netw. 2014;12:759–61.
4. Martin HL, Smith L, Tomlinson DC. Multidrug-resistant breast cancer: current perspectives. Breast Cancer (Dove Med Press). 2014;6:1–13.
5. Sorlie T, Perou CM, Fan C, Geisler S, Aas T, Nobel A, et al. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther. 2006;5:2914–8.
6. Nana-Sinkam SP, Croce CM. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther. 2013;93:98–104.
7. Gromak N. Intronic microRNAs: a crossroad in gene regulation. Biochem Soc Trans. 2012;40:759–61.
8. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell. 2003;113:673–6.
9. Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.
10. Farazi TA, Hoell JI, Morozov P, Tuschl T. MicroRNAs in human cancer. Adv Exp Med Biol. 2013;774:1–20.
11. Cobleigh MA. Other options in the treatment of advanced breast cancer. Semin Oncol. 2011;Suppl 2:S11-16.
12. Srivastava A, Tiwari R, Srivastava V, Singh TB, Asthana RK. Fresh water cyanobacteria Geitlerinema sp. CCC728 and Arthrospira sp. CCC729 as an anticancer drug resource. PLoS One. 2015;10:e0136838.
13. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–8.
14. Prathapan A, Vineetha VP, Raghu KG. Protective effect of Boerhaavia diffusa L. against mitochondrial dysfunction in angiotensin II induced hypertrophy in H9c2 cardiomyoblast cells. PLoS One. 2014;9:e96220.
15. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001;292:727–30.
16. Merino D, Lok SW, Visvader JE, Lindeman GJ. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer. Oncogene. 2015.
17. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2:647–56.
18. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafrè SA, et al. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem. 2007;282:23716–24.
19. Ali AY, Farrand L, Kim JY, Byun S, Suh JY, Lee HJ, et al. Molecular determinants of ovarian cancer chemoresistance: new insights into an old conundrum. Ann N Y Acad Sci. 2012;1271:58–67.
20. Wei HM, Qin SK, Yin XJ, Chen YL, Hua HQ, Wang L, et al. Inhibition and mechanism on combination of recombinant human endostatin and cisplatin in mouse model bearing S180 tumor ascite. Chin J Cancer Prev Treat. 2015;22:442–6.
21. Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del Monte G, et al. Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol. 2003;21:927–31.
22. Hu J, Xu C, Cheng B, Jin L, Li J, Gong Y, Lin W, Pan Z, Pan C. Imperatorin acts as a cisplatin sensitizer via downregulating Mcl-1 expression in HCC chemotherapy. Tumour Biol. 2015.
23. Ou Y, Zhai D, Wu N, Li X. Downregulation of miR-363 increases drug resistance in cisplatin-treated HepG2 by dysregulating Mcl-1. Gene. 2015.
24. Adi Harel S, Bossel Ben-Moshe N, Aylon Y, Bublik DR, Moskovits N, Toperoff G, et al. Reactivation of epigenetically silenced miR-512 and miR-373 sensitizes lung cancer cells to cisplatin and restricts tumor growth. Cell Death Differ. 2015;22:1328–40.
25. Yin W, Nie Y, Zhang Z, Xie L, He X. miR-193b acts as a cisplatin sensitizer via the caspase-3-dependent pathway in HCC chemotherapy. Oncol Rep. 2015;34:368–74.
26. Wang X, He X, Hu S, Sun A, Lu C. Involvement of Bim in Photofrin-mediated photodynamically induced apoptosis. Cell Physiol Biochem. 2015;35:1527–36.
27. He H, Li DW, Yang LY, Fu L, Zhu XJ, Wong WK, et al. A novel bifunctional mitochondria-targeted anticancer agent with high selectivity for cancer cells. A novel bifunctional mitochondria-targeted anticancer agent with high selectivity for cancer cells. Sci Rep. 2015;5:13543.
28. Zhao L, Feng Y, Shi A, Zong Y, Wan M. Apoptosis induced by microbubble-assisted acoustic cavitation in K562 cells: the predominant role of the cyclosporin A-dependent mitochondrial permeability transition pore. Ultrasound Med Biol. 2015;41:2755–64.
29. Weber K, Harper N, Schwabe J, Cohen GM. BIM-mediated membrane insertion of the BAK pore domain is an essential requirement for apoptosis. Cell Rep. 2013;5:409–20.